Mycophenolate Mofetil for the Treatment of Systemic Sclerosis

Author(s): Manisha Naik, Max Shenin, Chris T. Derk

Journal Name: Letters in Drug Design & Discovery

Volume 5 , Issue 2 , 2008

Become EABM
Become Reviewer


Mycophenolate mofetil, an inosine monophosphate dehydrogenase inhibitor, that inhibits the de novo pathway of guanosine nucleotide synthesis, inhibits proliferative responses of T and B lymphocytes as well as antibody production by B-lymphocytes. It is indicated for the prophylaxis of organ rejection after allogeneic cardiac, hepatic and renal transplants. It has also been recently used with good success in patients with lupus nephritis. Based on these actions mycophenolate mofetil appears to be a novel agent in the treatment of systemic sclerosis.

Keywords: Mycophenolate mofetil, Mycophenolic acid, Fibsosis, Systemic sclerosis, Scleroderma, Treatment

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [134 - 136]
Pages: 3
DOI: 10.2174/157018008783928454
Price: $65

Article Metrics

PDF: 4